NewsMedicinal CannabisChildren's Dutch Epilepsy Cannabis Medicines Will Be Made In...

Children’s Dutch Epilepsy Cannabis Medicines Will Be Made In The UK To Overcome Import Impasse


A PERMANENT solution to the import impasse on children’s epilepsy cannabis medication has emerged with the Dutch manufacturer set to see the medicines made in the UK.

However, the Transvaal Pharmacy, which is based in the Hague, says this will not be in operation for at least a few months meaning a short-term solution still needs to be found.

A spokesperson for the Dutch pharmacy said it understood the UK Government is still working on this and a statement is expected soon – (see end of article for an update on this).

BusinessCann approached The Department Department of Health and Social Care yesterday evening an is awaiting a response.

Parents Fearful For Their Children’s Lives

In late December it emerged that over 40 children with epilepsy in the UK would no longer be able receive their cannabis medicines from Holland.

A combination of Brexit and the need to produce the medicines to the recognised EU-GMP standards meant the previous method of importing the medicines from the Transvaal Pharmacy in the Hague, was terminated.

This left the 40 families facing a bleak 2021 as their children rely on these medicines to manage their seizures.

Hannah Deacon, the mother of nine-year-old Alfie Dingley – who lives with a rare and severe form of epilepsy – told how she fears her son could die.

Last night in an email conversation with BusinessCann the Transvaal Pharmacy explained that it had been in contact with the UK Government in order to secure a solution.

Production Planned For UK

It said: “For the short term solution the UK government will come with a statement. They are still working on it.

“For the long term we are also in contact with the UK government for the possibilities. In about one month we will have a plan.

“We are planning to come over to the UK for a transfer of the production method as a long-term solution.”

Respected UK cannabis clinician Prof Mike Barnes is a Director of the Maple Tree Medical Cannabis Consultancy, along with Ms Deacon, and has written some of the Transvaal scripts.

Government Needs To Get A Move On

He welcomed developments telling BusinessCann: “I am really pleased to hear that a solution is in sight. That is good news, but we still need to hear more from the Government in the short-term and it needs to get a move on, quickly.”

The cannabis medicines used by the UK children are made by the Transvaal pharmacy from cannabis flowers cultivated by fellow Dutch business Bedrocan.

We are planning to come over to the UK for a transfer of the production method as a long-term solution


As Prof Barnes explained in BusinessCann yesterday these particular flowers and production processes are bespoke and difficult to replicate.

And, this is why the parents and the children are uncomfortable switching to the alternative products available in the UK.

One company which sells a range of medical cannabis products to treat epilepsy is Grow Pharma. Its CEO Pierre van Weperen said it was pleased to hear a resolution was in sight.

He went on to say that Grow Pharma and its partner IPS Pharma will today produce a product with similar profiles to the Tranvaal product – using the same Bedrocan flowers – and allow the children currently using the Dutch medicines to try it at no cost.

He added: “We feel it is important act on this now, and we are prepared to help these children and their parents immediately.”

NB. On Thursday evening (January 21) The Dutch govt says it will permit the supply of the medicines until July 1, 2021 as an emergency measure for the children.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


  1. This is great news for these 40+Families but Mat Hancock has already lied to them. Time for Department of Cannabis and Cannabinoids with people who actually know about the Endocannabinoid System!

Comments are closed.

Latest news

MGC Pharmaceuticals Releases Update On CimetrA Clinical Trial Progress In USA

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development...

European Cannabis Stocks Review: Akanda’s ‘Concerned Shareholders’ Oust All Directors Except CEO To Prevent ‘Potentially Irreparable Harm’ – More From Goodbody Health & Chill...

It has been another week of positive developments for the cannabis industry across Europe, with yet more markets making...

Analysis Shows UK Market Could Grow To Over £1bn By 2026 As London Prepares To Host Europe’s Leading Cannabis Conference

ANALYSIS shows UK market could grow to over £1bn by 2026 as London prepares to host Europe’s leading cannabis...

Medical Cannabis Could Be Available In Spain By The End Of The Year

SPAIN could now see the regulation and distribution of medical cannabis rolled out before the end of the year...

New UK Company Heralds Its ‘Unique’ Medical Cannabis Delivery Mechanism

CANNABIS extraction and formulations specialist 113 Botanicals is in the process of securing Good manufacturing Practice (GMP) compliance for...

German Cannabis Bill By Year End With Adult-Use Launch Likely In Early 2024

GERMANY’s draft cannabis law should be ready by the end of the year with the launch of its adult-use...

Must read

You might also likeRELATED
Recommended to you